KED
Evidence Grade E — Very limited evidence. 6 published studies. 0 registered clinical trials.
Vesugen is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target blood vessel lining (vascular endothelium). Among Khavinson vascular peptides, it has the strongest mechanistic data, with quantitative cell proliferation measurements and specific DNA binding studies. No human clinical trials have been conducted and it has no regulatory approval.
6 published studies: 3 human, 3 animal, 1 in-vitro, 0 reviews
Vesugen has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. In vitro studies in vascular tissue cultures reported increased Ki-67 expression (a cell proliferation marker), with greater effects observed in senescent versus young tissue cultures.
As with other Khavinson bioregulator peptides, the proposed vascular-targeting mechanisms and gene-regulatory effects have not been independently validated or tested in clinical trials. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Vesugen binds to specific DNA sequences in gene promoter regions, with a validated gene target (Ki-67/MKI67) involved in cell proliferation. Molecular docking studies and vascular tissue culture experiments have been published. These mechanisms are based on in vitro and computational work from the originating research group.
Research suggests approximately 8-12 indexed studies exist, with quantitative data on cell proliferation markers and DNA binding that provide stronger mechanistic grounding than most Khavinson peptides. Effects were more pronounced in aged versus young tissue cultures — an observation consistent with the bioregulation theory. However, virtually all research originates from a single laboratory. No large controlled human trials, no pharmacokinetic data, and no independent Western replication exist. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
